Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, CHIEF TECHNICAL OFFICER | February 25, 2025 | February 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date February 25, 2025 · Filed February 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 173,756 |
Ending reported balance
After 2025-02-27 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2025-02-25 · Sale · Disposed 9,300 · Balance 186,153 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2025-02-25 · Sale · Disposed 700 · Balance 185,453 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2025-02-26 · Sale · Disposed 9,400 · Balance 176,053 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2025-02-26 · Sale · Disposed 600 · Balance 175,453 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2025-02-27 · Sale · Disposed 1,597 · Balance 173,856 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2025-02-27 · Sale · Disposed 100 · Balance 173,756 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.
F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2024 Filed Feb 20, 2024 23:59 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 4,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004477 · form4-02202024_110252.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:59 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 3,097 | $36.10 | $111,801.70 |
DisclosureSEC source: 0001415889-24-004477 · form4-02202024_110252.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,983 F1 · shares: The reported disposition of 3,097 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:59 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 6,112 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004477 · form4-02202024_110252.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:47 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 3,386 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004187 · form4-02162024_100206.xml · derivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,386 Underlying: Common Stock · 3,386 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:47 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 3,832 | $35.91 | $137,607.12 |
DisclosureSEC source: 0001415889-24-004187 · form4-02162024_100206.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,968 F3 · shares: The reported disposition of 3,832 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:47 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 8,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004187 · form4-02162024_100206.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,800 F2 · security: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:47 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 1,208 | $35.91 | $43,379.28 |
DisclosureSEC source: 0001415889-24-004187 · form4-02162024_100206.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,321 F1 · shares: The reported disposition of 1,208 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:47 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 3,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004187 · form4-02162024_100206.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 8,133 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-003529 · form4-02132024_090202.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,901 | $35.49 | $102,956.49 |
DisclosureSEC source: 0001415889-24-003529 · form4-02132024_090202.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,143 F1 · shares: The reported disposition of 2,901 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 8,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-003529 · form4-02132024_090202.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2024 Filed Jan 18, 2024 21:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $12.07 | $0.00 |
DisclosureSEC source: 0001415889-24-001520 · form4-01182024_090126.xml · derivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,885 Underlying: Common Stock · 10,000 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F3 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| January 17, 2024 Filed Jan 18, 2024 21:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $36.00 | $360,000.00 |
DisclosureSEC source: 0001415889-24-001520 · form4-01182024_090126.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $36.00 to $36.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 17, 2024 Filed Jan 18, 2024 21:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $12.07 | $120,700.00 |
DisclosureSEC source: 0001415889-24-001520 · form4-01182024_090126.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $12.07 | $0.00 |
DisclosureSEC source: 0001415889-24-001520 · form4-01182024_090126.xml · derivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,885 Underlying: Common Stock · 10,000 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F3 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $36.00 | $360,000.00 |
DisclosureSEC source: 0001415889-24-001520 · form4-01182024_090126.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $12.07 | $120,700.00 |
DisclosureSEC source: 0001415889-24-001520 · form4-01182024_090126.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 00:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $12.07 | $0.00 |
DisclosureSEC source: 0001415889-23-016423 · form4-12142023_121225.xml · derivative · entry 9 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,885 Underlying: Common Stock · 10,000 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F6 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 00:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $40.39 | $403,940.00 |
DisclosureSEC source: 0001415889-23-016423 · form4-12142023_121225.xml · nonDerivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F4 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.20 to $40.72. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 00:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $12.07 | $120,700.00 |
DisclosureSEC source: 0001415889-23-016423 · form4-12142023_121225.xml · nonDerivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 00:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,467 | $0.00 Strike: $12.07 | $0.00 |
DisclosureSEC source: 0001415889-23-016423 · form4-12142023_121225.xml · derivative · entry 8 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,885 Underlying: Common Stock · 1,467 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F6 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 00:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 8,533 | $0.00 Strike: $13.81 | $0.00 |
DisclosureSEC source: 0001415889-23-016423 · form4-12142023_121225.xml · derivative · entry 7 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,533 shares Expires 2025-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F5 · derivative.exercise_date: This option was granted on February 4, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 00:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 643 | $40.47 | $26,019.00 |
DisclosureSEC source: 0001415889-23-016423 · form4-12142023_121225.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.25 to $40.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.315 to $40.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 00:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 9,357 | $39.58 | $370,303.28 |
DisclosureSEC source: 0001415889-23-016423 · form4-12142023_121225.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,554 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.25 to $40.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 00:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 1,467 | $12.07 | $17,706.69 |
DisclosureSEC source: 0001415889-23-016423 · form4-12142023_121225.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 00:48 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 8,533 | $13.81 | $117,840.73 |
DisclosureSEC source: 0001415889-23-016423 · form4-12142023_121225.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $13.81 | $0.00 |
DisclosureSEC source: 0001415889-23-015195 · form4-11162023_091135.xml · derivative · entry 9 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,533 Underlying: Common Stock · 10,000 shares Expires 2025-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F4 · derivative.exercise_date: This option was granted on February 4, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $39.79 | $397,880.00 |
DisclosureSEC source: 0001415889-23-015195 · form4-11162023_091135.xml · nonDerivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.335 to $40.155. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $13.81 | $138,100.00 |
DisclosureSEC source: 0001415889-23-015195 · form4-11162023_091135.xml · nonDerivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,708 | $0.00 Strike: $16.78 | $0.00 |
DisclosureSEC source: 0001415889-23-015195 · form4-11162023_091135.xml · derivative · entry 8 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 292 Underlying: Common Stock · 1,708 shares Expires 2028-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F5 · derivative.exercise_date: This option was granted on July 2, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 8,292 | $0.00 Strike: $13.81 | $0.00 |
DisclosureSEC source: 0001415889-23-015195 · form4-11162023_091135.xml · derivative · entry 7 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,533 Underlying: Common Stock · 8,292 shares Expires 2025-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F4 · derivative.exercise_date: This option was granted on February 4, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 1,708 | $39.08 | $66,746.93 |
DisclosureSEC source: 0001415889-23-015195 · form4-11162023_091135.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $38.75 to $39.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 1,708 | $16.78 | $28,660.24 |
DisclosureSEC source: 0001415889-23-015195 · form4-11162023_091135.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 8,292 | $39.08 | $324,043.07 |
DisclosureSEC source: 0001415889-23-015195 · form4-11162023_091135.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $38.75 to $39.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:18 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 8,292 | $13.81 | $114,512.52 |
DisclosureSEC source: 0001415889-23-015195 · form4-11162023_091135.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| October 17, 2023 Filed Oct 17, 2023 23:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001415889-23-014366 · form4-10172023_111007.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,099 Underlying: Common Stock · 10,000 shares Expires 2030-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2022. F2 · derivative.exercise_date: This option was granted on February 10, 2020 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| October 17, 2023 Filed Oct 17, 2023 23:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $36.52 | $365,200.00 |
DisclosureSEC source: 0001415889-23-014366 · form4-10172023_111007.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2022. Read SEC document |
| October 17, 2023 Filed Oct 17, 2023 23:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $19.98 | $199,800.00 |
DisclosureSEC source: 0001415889-23-014366 · form4-10172023_111007.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2022. Read SEC document |
| September 19, 2023 Filed Sep 19, 2023 20:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001415889-23-013397 · form4-09192023_080951.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,099 Underlying: Common Stock · 10,000 shares Expires 2030-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2022. F3 · derivative.exercise_date: This option was granted on February 10, 2020 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| September 19, 2023 Filed Sep 19, 2023 20:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $39.10 | $390,980.00 |
DisclosureSEC source: 0001415889-23-013397 · form4-09192023_080951.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2022. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $38.885 to $39.29. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 19, 2023 Filed Sep 19, 2023 20:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $19.98 | $199,800.00 |
DisclosureSEC source: 0001415889-23-013397 · form4-09192023_080951.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2022. Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 21:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 8,075 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001415889-23-012570 · form4-08232023_090830.xml · derivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,099 Underlying: Common Stock · 8,075 shares Expires 2030-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: This option was granted on February 10, 2020 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 21:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,925 | $0.00 Strike: $18.41 | $0.00 |
DisclosureSEC source: 0001415889-23-012570 · form4-08232023_090830.xml · derivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,580 Underlying: Common Stock · 1,925 shares Expires 2028-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 21:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 8,075 | $42.41 | $342,436.53 |
DisclosureSEC source: 0001415889-23-012570 · form4-08232023_090830.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.15 to $42.735. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 21:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 8,075 | $19.98 | $161,338.50 |
DisclosureSEC source: 0001415889-23-012570 · form4-08232023_090830.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 21:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 1,925 | $42.41 | $81,633.48 |
DisclosureSEC source: 0001415889-23-012570 · form4-08232023_090830.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,911 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.15 to $42.735. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 21:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 1,925 | $18.41 | $35,439.25 |
DisclosureSEC source: 0001415889-23-012570 · form4-08232023_090830.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 20:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 2,825 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001415889-23-011318 · form4-07192023_080758.xml · derivative · entry 7 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,627 Underlying: Common Stock · 2,825 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 20:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 7,175 | $0.00 Strike: $13.81 | $0.00 |
DisclosureSEC source: 0001415889-23-011318 · form4-07192023_080758.xml · derivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,825 Underlying: Common Stock · 7,175 shares Expires 2025-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted on February 4, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 20:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $18.41 | $0.00 |
DisclosureSEC source: 0001415889-23-011318 · form4-07192023_080758.xml · derivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,505 Underlying: Common Stock · 10,000 shares Expires 2028-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.